{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:40Z","timestamp":1792831060853,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474064"],"award-info":[{"award-number":["82474064"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bioorg.2026.110559","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:45:03Z","timestamp":1790095503000},"page":"110559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rational design of chromeno[8,7-d]oxazoles as CDK16-directed inhibitors with improved solubility and antitumor activity"],"prefix":"10.1016","volume":"183","author":[{"given":"Xupeng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuibin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoguang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingming","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110559_bb0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110559_bb0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110559_bb0015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bioorg.2026.110559_bb0020","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110559_bb0025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110559_bb0030","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110559_bb0035","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110559_bb0040","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110559_bb0045","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.110559_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116106","article-title":"Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation","volume":"265","author":"Zuo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110559_bb0055","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110559_bb0060","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.bioorg.2026.110559_bb0065","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1002\/j.1460-2075.1992.tb05360.x","article-title":"A family of human cdc2-related protein kinases","volume":"11","author":"Meyerson","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.bioorg.2026.110559_bb0070","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1128\/MCB.06261-11","article-title":"Cyclin-dependent kinase 16\/PCTAIRE kinase 1 is activated by Cyclin Y and is essential for spermatogenesis","volume":"32","author":"Mikolcevic","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bioorg.2026.110559_bb0075","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.biopha.2018.04.080","article-title":"CDK16 overexpressed in non-small cell lung cancer and regulates cancer cell growth and apoptosis via a p27-dependent mechanism","volume":"103","author":"Wang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.110559_bb0080","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7150\/thno.21963","article-title":"CDK16 phosphorylates and degrades p53 to promote radioresistance and predicts prognosis in lung cancer","volume":"8","author":"Xie","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2026.110559_bb0085","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.258831","article-title":"PCTAIRE1 promotes mitotic progression and resistance against antimitotic and apoptotic signals","volume":"135","author":"Gillani","year":"2022","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bioorg.2026.110559_bb0090","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13046-022-02362-w","article-title":"CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1","volume":"41","author":"Li","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110559_bb0095","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1042\/BCJ20160941","article-title":"Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16","volume":"474","author":"Dixon-Clarke","year":"2017","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2026.110559_bb0100","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1021\/ml4000063","article-title":"Discovery of dabrafenib: a selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors","volume":"4","author":"Rheault","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110559_bb0105","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/1878-0261.12152","article-title":"Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition","volume":"12","author":"Phadke","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110559_bb0110","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","article-title":"Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036","volume":"19","author":"Chan","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.110559_bb0115","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1158\/1535-7163.MCT-17-0241","article-title":"The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2Hi macrophages in breast cancer and pancreatic neuroendocrine tumors","volume":"16","author":"Harney","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110559_bb0120","first-page":"183","article-title":"Rational design of oxazolonylflavone derivatives as novel CDK4\/9 inhibitors with potent antitumor efficacy and oral bioavailability","volume":"69","author":"Huang","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110559_bb0125","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1021\/acs.jmedchem.0c01754","article-title":"Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables short duration of target engagement for the treatment of hematological malignancies","volume":"63","author":"Barlaam","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110559_bb0130","article-title":"Chai-1: decoding the molecular interactions of life","author":"Chai Discovery","year":"2024","journal-title":"bioRxiv"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:05:42Z","timestamp":1792829142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826010953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":26,"alternative-id":["S0045206826010953"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110559","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design of chromeno[8,7-d]oxazoles as CDK16-directed inhibitors with improved solubility and antitumor activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110559"}}